Answers are grounded in this paper and cite their sources.
Expert consensus defines scientific and ethical prerequisites for immune tolerance trials in heart and lung recipients, highlighting the need for large animal validation.
INTRODUCTION The National Heart, Lung and Blood Institute (NHLBI) convened the Heart and Lung Tolerance Working Group on December 4, 2000 in Bethesda, MD to determine whether data from animal studies are sufficient to justify initiating tolerance induction protocols in human heart or lung transplant patients. The Working Group comprised experts in the basic and clinical aspects of heart and lung transplantation, transplantation immunology, and bioethics, assisted by staff from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Department of Health and Human Services (DHHS) Office for Human Research Protections. The impetus for this Working Group arose from several arenas. In recent years, there have been discussions over the applicability of experimental studies of immune tolerance induction to human heart and lung transplantation. In addition, some members of the thoracic transplant community believe that the greater susceptibility of thoracic organ allografts to chronic rejection and late graft failure warrants the inclusion of heart and possibly lung transplant patients in immune tolerance studies now. However, in April 1998, the National Institute of Allergy and Infectious Diseases (NIAID) convened an expert panel to develop guidelines for the design, conduct, and monitoring of scientifically and ethically acceptable clinical trials to evaluate the safety and efficacy of new approaches to achieve immune tolerance in transplant recipients (1). The NIAID panel concluded that clinical trials should not be initiated in settings such as heart and liver transplantation where the failure to induce tolerance could be life-threatening because of the absence of a rescue strategy analogous to dialysis. The Immune Tolerance Network (ITN), a joint endeavor of the NIAID and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH), and the Juvenile Diabetes Foundation, currently is testing promising new clinical protocols for tolerance induction in islet cell and kidney transplant patients. In the period since the 1998 report, substantial progress in basic and preclinical studies of tolerance induction makes it timely to reconsider the merits of clinical tolerance induction protocols in heart and lung transplant patients. For instance, using a clinically relevant, nonmyeloablative conditioning regimen to achieve mixed hematopoietic chimerism in a miniature swine, Schwarze et al. (2) were able to obtain long-term cardiac allograft survival without chronic immunosuppressive therapy, significant vasculopathy, or graft-versus-host disease. The thoracic transplant community is understandably eager to avail their patients of the benefits successful tolerance induction may provide. The specific charge to this Working Group was to determine if it would be scientifically and ethically justified to proceed with clinical protocols for tolerance induction in heart or lung transplant recipients at this time. BACKGROUND Late graft failure due to chronic rejection is one of the most pressing problems in thoracic organ transplantation today. Cardiac allograft vasculopathy (CAV) and obliterative bronchiolitis (OB) can be detected as early as a few months after transplantation. The incidence of CAV is about 10% per year; OB or the associated syndrome (OBS) has an incidence of at least 15% per year and a prevalence of 60–80% at 5 years (3). Although newer immunosuppressive medications have reduced the incidence of acute rejection of heart and lung allografts in the first year posttransplantation, these therapeutic improvements have not significantly altered long-term clinical outcomes. In contrast, studies of heart transplantation in rodents and preclinical large animal models have demonstrated that the induction of immune tolerance can effectively mitigate, and in some cases, prevent the development of CAV (4). Based on these experimental findings, the induction of donor-specific immune tolerance in humans may not only achieve long-term graft survival without the need for nonspecific, life-long immunosuppressive therapy, but may also diminish or eliminate the problem of chronic rejection. Because standard pharmacological immunosuppressive therapy generally yields excellent short-term results, new tolerance therapies would need to have highly successful outcomes sustained over a prolonged period to justify their use. Complicating this is the evidence that standard immunosuppressive therapy may block certain immune signaling pathways necessary to induce at least some types of tolerance. As clearly stated by Rose et al. (1), a major ethical dilemma in moving forward with clinical trials of tolerance induction in thoracic organ transplantation is the probability that adequate evaluation of the efficacy and safety of tolerance protocols may involve withholding or significantly altering standard immunosuppressive therapy. In other words, it may be difficult to incorporate new tolerance induction strategies within the context of standard immunosuppressive treatment regimens. The issue becomes increasingly complex when considering thoracic organ transplantation for which there is no rescue should treatment fail. With the early surveillance strategies that are used to monitor thoracic transplants, it is thought, at this point, that tolerance failure could be reversed with immunosuppressive drug therapy. However, whether this will prove to be true in the clinical setting remains to be seen. Because of the complex ethical issues surrounding the introduction of tolerance induction therapies into the clinic, care must be taken to ensure that patients fully understand the risks and benefits of participating in such a trial. This may require going beyond the standard protocol approval of an IRB and blanket consent form, and might include the possibility of a third party patient advocate, unrelated to the trial, and the use of tiered consent. DISCUSSION The Working Group was given the charge of examining what is known about tolerance induction from basic and clinical studies and determining 1) whether there are adequate data to ethically proceed with clinical studies for heart and lung patients at this time and 2) if the current information is inadequate, what information would be needed to allow such trials to be considered? To make recommendations, the Working Group first addressed a number of key issues: Are there experimental protocols, in either small or large animals, which effectively and consistently induce immune tolerance in recipients of heart allografts or in recipients of lung allografts? The panel acknowledged that, although donor-specific tolerance to heart allografts has been achieved using numerous strategies in rodent models, it has proven difficult to reproduce similar success in large animals, such as non-human primates. However, recent proof-of-principle studies have achieved heart allograft tolerance in swine (5). When hearts and kidneys from the same donors were transplanted simultaneously into class I-disparate recipients treated with a brief course of cyclosporine, the hosts became tolerant to their cardiac allografts, survived long-term, and did not develop any evidence of coronary allograft vasculopathy. As mentioned above, the application of mixed chimerism protocols to heart transplantation in large animals has also proven successful in inducing long-term and stable tolerance (2). Finally, strategies using costimulatory blockade have shown promise in pig and primate heart transplant recipients (6,7). In contrast, immune tolerance to lung allografts has not been achieved consistently in either small or large animals. Some members believed that current experimental models of lung transplantation were not adequate and noted that tolerance research for lung transplantation has lagged behind tolerance research on other organs. It was believed that investigators attempting to achieve tolerance in lung recipients need more small animal studies in addition to large animal studies. There are a variety of issues in lung transplantation that extend beyond basic immunology. Finally, it was noted that the success of a particular tolerance protocol in a large animal system does not guarantee that the same protocol will be successful when transferred to a clinical setting. Is the induction of tolerance to heart or to lung allografts biologically different from the induction of tolerance to other organ allografts such as kidneys? Is there an organ-specific component to tolerance induction? Translating tolerance protocols from one organ to another has been equally elusive. For example, experimental regimens that effectively induce tolerance to kidney allografts sometimes fail to induce tolerance to heart allografts (Kawai T, et al., manuscript submitted) (5). Comparative studies demonstrate that the induction of tolerance to cardiac allografts can be more difficult to achieve than for kidney allografts. Because success with a clinical tolerance protocol in kidney recipients will not necessarily ensure success in heart and lung recipients, the panel agreed that organ-specific testing of clinical tolerance protocols was mandatory. Has tolerance induction been attempted in human heart or lung recipients? If so, what are the data from these clinical studies? Are there scientifically viable and ethically acceptable tolerance induction protocols presently available to human heart or lung recipients? Are there such protocols on the horizon at this time? The only attempts at clinical tolerance induction in thoracic organ transplant recipients have been early phase I studies using either donor peripheral blood mononuclear cells (PBMC) transfusions in unconditioned recipients (8,9) or intrathymic injection of donor antigen in a small number of patients receiving standard triple drug immunosuppression (Griffiths BP, personal communication). There have been no attempts to aggressively wean or eliminate immunosuppression in these recipients to date. No specific protocols were identified as being imminently ready for large-scale recruitment. Are there rescue therapies available if tolerance induction fails in heart or lung recipients? Would standard immunosuppressive therapies for acute rejection suffice? Would left ventricular assist devices provide an acceptable safety net in the case of heart transplant recipients? It was agreed that it would not be ethical to go forward with clinical studies without providing reasonable rescue therapy. There was considerable debate about what options are available for rescue therapy for clinical trials once a protocol has shown adequate preclinical success. Although left ventricular mechanical assist devices (LVADs) were proposed as a rescue therapy for heart recipients, the consensus of the panel was that LVADs, because of FDA restrictions and serious LVAD-related complications such as infections and thrombosis, could not truly be considered a safety net in the same way that dialysis is a safety for kidney transplant patients. Instead, there was consensus that any rejection due to failure of a tolerance protocol could be detected early, before significant organ damage occurred, because heart and lung transplant patients receive frequent, protocol biopsies or bronchial alveolar lavage (BAL). Furthermore, there was optimism that the institution of standard immunosuppressive therapies to treat acute rejection would be an acceptable “rescue” therapy because 95% of acute rejection can be reversed with currently available drugs. What would be the clinical end-points or markers for successful thoracic tolerance protocols? The participants agreed that measures of what would constitute success in the clinical setting must be clearly identified. There was lengthy discussion about using chronic rejection as one measure of the success of a tolerance protocol. A unique feature of heart and lung transplantation is the long-term surveillance (BAL for lungs and angiography, intravascular ultrasound, and endomyocardial biopsy for hearts) of the allograft to evaluate both the acute and chronic rejection process. Serial analyses of intimal thickening and pulmonary function studies, in addition to the availability of tissue and graft infiltrating cells over the life of the recipient, make chronic rejection an attractive end-point in thoracic organ tolerance protocols. Furthermore, because CAV and OB develop within 3–5 years after transplantation, the results of therapy could be assessed relatively early. In light of the responses to the above questions, would it be scientifically and ethically appropriate to go forward with clinical studies of tolerance induction now? Because no true tolerance protocol was identified as being scientifically and ethically appropriate for clinical trials at the present time, the answer to the question is no. However, a number of intriguing protocols appear to be on the horizon and are being studied in large animal models. These include the induction of mixed chimerism, donor thymus transplantation, and host thymus modulation. When adequate success is achieved in preclinical studies, the group thought that it would be ethically acceptable to test these protocols in thoracic transplant patients. Which patient population(s) would be appropriate to include in heart and lung tolerance induction protocols from a scientific and ethical viewpoint? Patient selection would be critical to optimize the risk/benefit ratio in clinical tolerance induction trials. In some ways, children were seen as having the most to gain from a successful tolerance protocol. Children have more years to lose from a shortened life expectancy and face a larger proportion of their lives subject to the morbidity of nonspecific immunosuppression and chronic rejection. This Working Group thought that when clinical studies could proceed, some protocols, such as those that required a functioning thymus, could and should be undertaken in children. To recruit an adequate number of patients, a collaborative effort among several centers would be required. If existing data do not justify going forward with clinical studies now, what preclinical data would be required to permit clinical tolerance studies to go forward? It was nearly universally accepted that tolerance protocols must be shown to be effective in a large animal model such as non-human primates or pigs before they can be ethically moved into the clinical arena. Thus, one strong recommendation of the Working Group was for more heart- and lung-specific studies to identify the mechanism of tolerance induction particularly in large animal models. RECOMMENDATIONS After thoughtful and detailed discussion of the information available from studies of tolerance induction in the transplant setting, the following recommendations were proposed by the Working Group as being key in moving the field forward to human clinical trials 1) The considerable morbidity and mortality associated with chronic rejection and life-long immunosuppression in thoracic organ transplant recipients confer urgency on the pursuit of clinically applicable tolerance induction protocols for heart and lung transplant recipients. 2) Once promising protocols aimed at inducing tolerance to heart or lung allografts have proven successful in preclinical large animal models, it would be ethically sound to test them in human adult and pediatric heart transplant recipients in attempts to induce tolerance and thereby prevent chronic rejection and reduce or eliminate life-long immunosuppression. 3) Because protocols of tolerance induction should prove successful in large animal models (e.g., swine and non-human primates) before being considered for translation to humans, and because tolerance protocols may not be transferable from one organ system to another, large animal models of thoracic organ transplantation need to be developed and refined to study organ-specific tolerance induction to heart and to lung allografts. 4) There is a special need for further study of all issues surrounding lung allograft rejection. Reliable and relevant small animal models of chronic lung rejection should be developed in tandem with large animal models for mechanistic studies of OB and to screen a wide range of tolerance induction strategies. 5) The study of existing transplant patients who have not developed significant CAV or OB posttransplant should be undertaken as they could yield important information concerning the immune mechanisms and genetic predispositions that contribute to the development of chronic rejection or alternatively to a state of immune tolerance. 6) Although no specific “safety net” is available to heart and lung transplant patients entered into trials of tolerance induction, thoracic organ recipients currently undergo frequent allograft surveillance procedures leading to the expectation that loss of allograft tolerance would be detected early as rejection and successfully treated using standard immunosuppressive agents. However, there is continuing need to develop early warning diagnostics to ensure that acute rejection is detected before severe or irreversible organ damage occurs and to distinguish between pathogenic and tolerogenic immune responses. 7) The absence of histological or functional manifestations of CAV or OB in patients on no immunosuppression or minimal immunosuppression, 3–5 years posttransplantation would be acceptable clinical markers of successful tolerance induction. However, novel “tolerance assays” should be assessed in parallel with these traditional monitoring strategies. 8) Tolerance studies present a number of ethical and regulatory concerns including the protection of the rights and welfare of the human subjects. Although not unique to tolerance studies, they nonetheless require careful consideration on a protocol-by-protocol basis. The protection of human subjects involved in such innovative research is best ensured by appropriately constituted, well informed Institutional Review Boards (IRBs) and when the research is conducted by investigators who are knowledgeable about and appreciate the ethical and regulatory aspects of the research. NHLBI HEART AND LUNG TOLERANCE WORKING GROUP List of Working Group Members Chairperson of Working Group:Joren C. Madsen, M.D., D.Phil., Associate Professor of Surgery, Department of Surgery, Massachusetts General Hospital, Harvard University Robert C. Bourge, M.D., Professor and Director, Division of Cardiovascular Disease, University of Alabama at Birmingham David Essayan, M.D., Medical Officer, Pharmacology and Toxicology Branch, Division of Clinical Trials Design and Analysis, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration Bartley P. Griffith, M.D., Henry T. Bahnson Professor of Surgery, Department of Surgery, University of Pittsburgh Jeffrey D. Hosenpud, M.D., Head, Transplant Cardiology, St. Luke’s Cardiac Transplant Program, Sinai Samaritan Medical Center Sharon Hunt, M.D., Professor, Department of Medicine, Falk Cardiovascular Research Center, Stanford University School of Medicine Chris Larsen, M.D., D.Phil., Associate Professor, Department of Surgery, Transplantation Immunology Laboratory, Emory University School of Medicine Kamal K. Mittal, D.V.M., Ph.D., Assurance Coordinator, Division of Policy and Assurance, Office for Human Research Protections (OHRP/OPHS/DHHS) Thalachallour Mohanakumar, D.V.M., Ph.D., Professor of Surgery, Department of Surgery, Washington University School of Medicine Philip Noguchi, M.D., Director, Division of Cellular Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration Soji F. Oluwole, M.D., Professor of Surgery, Department of Surgery, Columbia University Richard N. Pierson III, M.D., Associate Professor of Surgery, Department of Cardiac and Thoracic Surgery, Vanderbilt University School of Medicine Robert Robbins, M.D., Assistant Professor, Department of Cardiothoracic Surgery, Stanford University School of Medicine Eric Rose, M.D., Professor and Chairman, Department of Surgery, Columbia University Bruce Rosengard, M.D., Assistant Professor of Surgery, Department of Surgery, University of Pennsylvania Daniel Rotrosen, M.D., Director, Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases David H. Sachs, M.D., Professor of Surgery, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard University Harold Y. Vanderpool, Ph.D., Th.M., Professor in the History of Philosophy, Institute for the Medical Humanities, University of Texas Medical Branch Robert Veatch, Ph.D., Professor of Medical Ethics, Senior Research Scholar, Kennedy Institute of Ethics, Georgetown University Alison Wichman, M.D., Deputy Director, Office of Human Subjects Research, Office of Intramural Research, National Institutes of Health Conference Organizers: Judith Massicot-Fisher, Ph.D., Health Scientist Administrator, Heart Development, Function, and Failure, Heart Research Program, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health Patricia Noel, Ph.D., Division of Lung Diseases , National Heart, Lung, and Blood Institute, National Institutes of Health
No takes yet. Share an insight, caveat, or question.
Massicot-Fisher et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: